BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) has earned a consensus rating of “Buy” from the ten brokerages that are presently covering the stock. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $6.71.

A number of equities analysts have recently weighed in on BCRX shares. FBR & Co reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 8th. JMP Securities lowered BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Wednesday, November 9th. Jefferies Group upped their price objective on BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 8th.

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.59 on Monday. The company’s 50-day moving average price is $4.78 and its 200 day moving average price is $4.01. The company’s market capitalization is $412.31 million. BioCryst Pharmaceuticals has a 52-week low of $1.63 and a 52-week high of $10.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.08. BioCryst Pharmaceuticals had a negative return on equity of 296.19% and a negative net margin of 313.02%. The business earned $7.80 million during the quarter, compared to analyst estimates of $5.94 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was down 29.1% on a year-over-year basis. On average, equities analysts expect that BioCryst Pharmaceuticals will post ($0.92) EPS for the current fiscal year.

In other BioCryst Pharmaceuticals news, VP Alane P. Barnes sold 8,357 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $4.27, for a total transaction of $35,684.39. Following the sale, the vice president now directly owns 79,377 shares in the company, valued at $338,939.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.80% of the company’s stock.

Large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth about $48,351,000. RTW Investments LLC increased its stake in shares of BioCryst Pharmaceuticals by 88.0% in the third quarter. RTW Investments LLC now owns 4,204,579 shares of the biotechnology company’s stock worth $18,542,000 after buying an additional 1,967,513 shares during the period. Ghost Tree Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $4,828,000. VHCP Management II LLC increased its stake in shares of BioCryst Pharmaceuticals by 22.0% in the second quarter. VHCP Management II LLC now owns 5,721,142 shares of the biotechnology company’s stock worth $16,248,000 after buying an additional 1,031,707 shares during the period. Finally, VHCP Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 78.5% in the second quarter. VHCP Management LLC now owns 1,005,104 shares of the biotechnology company’s stock worth $2,854,000 after buying an additional 442,161 shares during the period. Institutional investors and hedge funds own 76.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/12/01/brokerages-set-biocryst-pharmaceuticals-inc-bcrx-target-price-at-6-71.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

5 Day Chart for NASDAQ:BCRX

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.